Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab - Reply

被引：0
|
作者：
Sorbero, Melony E. S. [1 ]
ElHassan, Nahed O. [1 ]
Hall, Caroline B. [1 ]
Stevens, Timothy P. [1 ]
Dick, Andrew W. [1 ]
机构：
[1] RAND Corp, Pittsburgh, PA 15213 USA
来源：
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE | 2007年 / 161卷 / 05期
关键词：
D O I：
10.1001/archpedi.161.5.520-a
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：520 / 520
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab
    Reeve, Carole A.
    Whitehall, John S.
    Buettner, Petra G.
    Norton, Robert
    Reeve, David M.
    Francis, Fleur
    [J]. JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2006, 42 (05) : 253 - 258
  • [2] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab
    Mahadevia, Parthiv J.
    Malinoski, Frank J.
    [J]. ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2007, 161 (05): : 519 - 520
  • [3] A review of cost-effectiveness of palivizumab for respiratory syncytial virus
    Hussman, Julia M.
    Li, Abby
    Paes, Bosco
    Lanctot, Krista L.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (05) : 553 - 567
  • [4] Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden
    Neovius, Kristian
    Buesch, Katharina
    Sandstrom, Kristina
    Neovius, Martin
    [J]. ACTA PAEDIATRICA, 2011, 100 (10) : 1306 - 1314
  • [5] Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review
    Mac, Stephen
    Sumner, Amanda
    Duchesne-Belanger, Samuel
    Stirling, Robert
    Tunis, Matthew
    Sander, Beate
    [J]. PEDIATRICS, 2019, 143 (05)
  • [6] Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: A cost-effectiveness analysis
    Lolfand, JH
    Touch, SM
    O'Connor, JP
    Chatterton, ML
    Moxey, ED
    Paddock, LE
    Nash, DB
    Desai, SA
    [J]. CLINICAL THERAPEUTICS, 2000, 22 (11) : 1357 - 1369
  • [7] COST-EFFECTIVENESS OF PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) WITH PALIVIZUMAB IN PRETERM INFANTS IN COLOMBIA
    Rosselli, D.
    Rueda, J. D.
    Ruiz, J. G.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A75 - A75
  • [8] COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS WITH PALIVIZUMAB FROM THE PERSPECTIVE OF A SOUTHERN US MEDICAID AGENCY
    Hampp, C.
    Kauf, T. L.
    Saidi, A.
    Winterstein, A. G.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A301 - A302
  • [9] Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK
    Narayan, Omendra
    Bentley, Anthony
    Mowbray, Katie
    Hermansson, Monika
    Pivonka, Dominic
    Kemadjou, Eric Ngonga
    Belsey, Jonathan
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1640 - 1652
  • [10] COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB WITH RISK FACTORS FOR RESPIRATORY SYNCYTIAL VIRUS PREVENTION
    Lee, M. Y.
    Lee, E. K.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A398 - A398
12345